NSCLC market will Increase to over $6 billion in 2021, fueled largely by the entry of seven new agents
The entry of seven new agents into the non-small cell lung cancer (NSCLC) drug market - and in particular the entry of two immunotherapies - in addition to increased use of drugs behemoth Pfizer’s (NYSE: PFE) Xalkori (crizotinib) will drive the NSCLC drug market to increase from $4.6 billion in 2011 to over $6 billion in 2021, according to the findings of a new study by health care advisory firm Decision Resources.
This growth will occur despite generic/biosimilar erosion of key agents used in the management of NSCLC. Sales of Eli Lilly’s (NYSE: LLY) Alimta (pemetrexed), a branded drug that dominated the 2011 NSCLC market, will weaken significantly in the second half of the forecast period owing to entry of generics.
Increasing personalized therapy
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze